Fig. 3
EHMT2 inhibitor exhibits anti-tumorigenesis effects in HCC. A The EHMT2 protein level in cells was determined by Western blot. Hep3B and Huh1 were treated with UNC0643 at the indicated conditions. n = 3. B Cell proliferation was determined by Ki67 staining. Three EHMT2−/− single clones of Hep3B and Huh1 in 2A were pooled together for the experiment. Cells were treated with UNC0642 at a dose of 5.0 μM for 2 days. Scale bar, 100 μm. n = 6 (mean ± SD); n.s, no significance; ***p < 0.001 by student's t-test. C MTT assay determined the cell growth curve of Hep3B cells. Cells in 3B were treated with UNC0642 at a dose of 5.0 μM for 3 days. n = 6 (mean ± SD); *p < 0.05, ** p < 0.01 and ***p < 0.001 by two-way ANOVA followed by post hoc Bonferroni multiple comparisons. D Soft agar assay determined the anchorage-independent growth ability of Hep3B cell lines. Cells in 3B were treated with UNC0642 at a dose of 5.0 μM every 3 days. The spheres with a diameter > 25 μm were considered as tumorspheres. n = 6 (mean ± SD); *p < 0.05 and ***p < 0.001 by student's t-test. E Final tumor weight of Hep3B xenograft assay. Cells in 3B were used. UNC0642 treated animals with a dose of 5 mg/kg via intraperitoneal injection with an interval of 3 days. n = 6 (mean ± SD); *p < 0.05 and ***p < 0.001 by student's t-test